P1400: THREE YEARS OUTCOMES OF PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS FOLLOWING ANTI CD19 CAR-T CELL THERAPY - A SINGLE CENTER EXPERIENCE

Ngā tūemi rite

• P1400: THREE YEARS OUTCOMES OF PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS FOLLOWING ANTI CD19 CAR-T CELL THERAPY - A SINGLE CENTER EXPERIENCE
  mā: Mika Geva, me ētahi atu.
  I whakaputaina: (2023-08-01)
• P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION
  mā: Ivetta Danylesko, me ētahi atu.
  I whakaputaina: (2023-08-01)
• P889: POINT-OF-CARE ANTI-BCMA CAR T-CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH-RISK RELAPSE/REFRACTORY MULTIPLE MYELOMA
  mā: Hila Magen, me ētahi atu.
  I whakaputaina: (2023-08-01)
• Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation
  mā: Yaara Yerushalmi, me ētahi atu.
  I whakaputaina: (2022-12-01)
• Microbiome-based prediction of allogeneic hematopoietic stem cell transplantation outcome
  mā: Oshrit Shtossel, me ētahi atu.
  I whakaputaina: (2025-07-01)